Platelet Hyperaggregability in Ischemic Cerebrovascular Disease and Effects of Aspirin

Summary

Platelet aggregation was studied in 24 patients in the chronic stage of ischemic cerebrovascular disease (CVD), with cerebral affluent and effluent blood, i.e., carotid arterial and internal jugular venous blood, and also with peripheral venous blood. Aggregation tests were performed at various final concentrations of sodium arachidonate (A.A.) and ADP. In 17 patients, not taking aspirin, platelet aggregability in jugular venous blood was significantly accentuated compared with that in arterial and peripheral venous blood. This tendency was more marked in the patients with cerebral artery stenosis and/or occlusion than in those with normal cerebral angiogram. In 7 patients taking 500 mg or more oral aspirin, aggregation differences across the brain were not observed and A.A. aggregation and the second phase of ADP aggregation were completely suppressed. These results suggest that a prophylactic administration of aspirin may be beneficial for patients in chronic stage of CVD.

Keywords

Platelet aggregation - Ischemic cerebrovascular disease - Cerebral affluent and effluent blood - Aspirin

• References

• 1 Andersen LA, Gormsen J. Platelet aggregation and fibrinolytic activity in transient cerebral ischemia. Acta Neurol Scand 1976; 55: 76-82
• 2 Ardlie NG, Kinlough RL, Schwartz CJ. In vitro thrombosis and platelet aggregation in myocardial infarction. Br Med J 1966; 1: 888-891
• 3 Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-929
• 4 Burch JW, Stanford N, Majerus PW. Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest 1978; 61: 314-319
• 5 Couch JR, Hassanein RS. Platelet aggregation, stroke, and transient ischemic attack in middle-aged and elderly patients. Neurology 1976; 26: 888-895
• 6 Danta G. Platelet adhesiveness in cerebrovascular disease. Atherosclerosis 1970; 11: 223-233
• 7 Di Minno G, Silver MJ, de Gaetano G. Prostaglandins as inhibitors of human platelet aggregation. Br J Haematol 1979; 43: 637-647
• 8 Dougherty JH, Levy DE. Platelet activation in acute cerebral ischemia. Lancet 1977; I: 821-824
• 9 Mehta J, Mehta P, Burger C, Pepine CJ. Platelet aggregation studies in coronary artery disease. Atherosclerosis 1978; 31: 169-175
• 10 Mustard JF, Perry DW, Kinlough-Rathbone RL, Packham MA. Factors responsible for ADP-induced release reaction of human platelets. Am J Physiol 1975; 228: 1757-1765
• 11 O’Brien JR. Effects of salicylate on human platelets. Lancet 1968; 1: 779-783
• 12 O’Brien JR, Etherington M, Jamieson S, Klaber MR, Lincoln SV. Platelet function long after arterial and venous thrombosis. Thrombos Diathes Haemorrh 1974; 31: 279-290
• 13 Packham MA, Mustard JF. Critical Review: Clinical pharmacology of platelets. Blood 1977; 50: 555-573
• 14 Patrono C, Ciabattoni G, Pinka E, Pugliese F, Castrucci G, De Salvo A, Satta MA, Pesker BA. Low dose aspirin and inhibition of thromboxane B₂ production in healthy subjects. Thromb Res 1980; 17: 317-327
• 15 Rance MJ, Jordan BJ, Nichols JD. A simultaneous determination of acetylsalicylic acid, salicylic acid and salicylamide in plasma by gas liquid chromatography. J Pharm Pharmacol 1975; 27: 425-429
• 16 Rao GHR, Reddy RK, White JG. Low dose aspirin, platelet function and prostaglandin synthesis: Influence of epinephrine and alpha adrenergic blockade. Prostaglandins Med 1981; 6: 485-494
• 17 Remuzzi G, Mecca G, Marchesi D, Livio M, de Gaetano G, Donati MB, Silver MJ. Platelet hyperaggregability and the nephrotic syndrome. Thromb Res 1979; 16: 345-354
• 18 Rowland M, Riegelman S, Harris PA, Sholkoff SD. Absorption kinetics of aspirin in man following oral administration of an aqueous solution. J Pharm Sci 1972; 61: 379-385
• 19 Sadurska B, Tacconi MT, di Minno G, Roncaglioni MC, Pangrazzi J, Donati MB, Bizzi A, Silver MJ. Plasma and platelet lipid composition and platelet aggregation by arachidonic acid in women on the pill. Thromb Haemostas 1981; 45: 150-153
• 20 Szczeklik A, Gryglewski RJ, Musial J, Grodzińska M, Serwońska M, Marcinkiewicz E. Thromboxane generation and platelet aggregation in survivals of myocardial infarction. Thromb Haemostas 1978; 40: 66-74
• 21 Uyama O, Matsumoto M, Fujisawa A, Kusunoki M, Yoneda S, Imaizumi M, Kimura K, Abe H. Plasma concentration of thromboxane B₂ in patients with hypertension or cerebrovascular disease. Prostaglandins Med 1981; 7: 199-207
• 22 Vargaftig BB, Chignaud M, Le Couedic JP, Benveniste J. One, two, three or more pathways for platelet aggregation. Acta Med Scand (Suppl) 1980; 642: 23-29
• 23 Weiss HJ, Lages BA. Possible congenital defect in platelet thromboxane synthetase. Lancet 1977; 1: 760-761
• 24 Winocour PD, Kinlough-Rathbone RL, Mustard JF. The effect of phospholipase inhibitor mepacrine on platelet aggregation, the platelet release reaction and fibrinogen binding to the platelet surface. Thromb Haemostas 1981; 45: 257-262
• 25 Yamazaki H, Sano T, Asano T, Hidaka H. Hyperaggregability of platelets in thromboembolic disorders. Thromb Res (Suppl) 1976; 8: 217-225
• 26 Zucker MB, Peterson J. Inhibition of adenosine diphosphate-induced secondary aggregation and other platelet function by acetylsalicylic acid ingestion. Proc Soc Exp Biol Med 1968; 127: 547-551